1025482-50-1

Basic information

• Product Name: acetic acid (6-chloro-pyridin-3-yl)-phenyl-methyl ester
• Synonyms: acetic acid (6-chloro-pyridin-3-yl)-phenyl-methyl ester
• CAS NO: 1025482-50-1
• Molecular Weight: 261.708
• Mol File: 1025482-50-1.mol

Chemical Properties

• CAS DataBase Reference: acetic acid (6-chloro-pyridin-3-yl)-phenyl-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: acetic acid (6-chloro-pyridin-3-yl)-phenyl-methyl ester(1025482-50-1)
• EPA Substance Registry System: acetic acid (6-chloro-pyridin-3-yl)-phenyl-methyl ester(1025482-50-1)

Safety Data

• Hazardous Substances Data: 1025482-50-1(Hazardous Substances Data)

Upstream product

• 80100-47-6 6-chloro-α-phenyl-3-pyridinemethanol 
• 108-24-7 acetic anhydride 

Downstream Products

• 1025482-64-7 3-(1-(3-cyanophenyl)-imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenylpropanoic acid 
• 1025482-57-8 methyl 3-(1-bromo-imidazo[1,5-a]pyridin-6-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-55-6 methyl 3-imidazo[1,5-a]pyridin-6-yl-2,2-dimethyl-3-phenylpropanoate 
• 1025482-54-5 methyl 3-(6-(formamidomethyl)pyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-53-4 methyl 3-(6-(aminomethyl)pyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-52-3 methyl 3-(6-cyanopyridin-3-yl)-2,2-dimethyl-3-phenylpropanoate 
• 1025482-35-2 C₂₆H₂₁ClFN₅OS 
• 1025482-34-1 C₂₇H₂₂ClFN₄OS 
• 1025482-33-0 C₂₆H₂₁F₂N₅OS 
• 1025482-32-9 C₂₇H₂₂F₂N₄OS 
• 1025482-36-3 C₂₇H₂₅N₅O₂S 
• 1025482-31-8 C₂₇H₂₂N₆OS 
• 1025482-30-7 C₂₈H₂₃N₅OS 
• 1025482-29-4 C₂₇H₂₂N₆OS 

Relevant articles and documents

Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3- phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core

A series of heterocyclic glucocorticoid receptor (GR) modulators with 2,2-dimethyl-3-phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core are described. Structure-activity relationships suggest a combination of H-bond acceptor and a 4-fluorophenyl moiety as being important structural components contributing to the glucocorticoid receptor binding and functional activity for this series of GR modulators.

MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1 and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I): its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein the group X is O or (Rx)(Ry); is heterocyclo or heteroaryl; E is —N—, —NR1—, —O—, —C(=O), —S—, —SO2—, or —CR2—; F is —N—, —NR1a, —O—, —C(=O), —S—, —SO2—, or —CR2a—; G is independently N, —NR1b—, —O—, —C(=O), —S—, —SO2— or —CR2b— provided that the heterocyclic ring formed does not contain a S—S or S—O bond and at least one of E, F and G is a hetero atom; and Ma, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, R4, R5a, R6, R7, X, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases employing said compounds.

MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory or immune associated diseases or disorders having the structure of formula I or an enantiomer, diastereomer, tautomer, or a pharmaceutically-acceptable salt, thereof, wherein: A is a 5-, 6-, or 7-membered heterocyclo or heteroaryl, each containing 1, 2, or 3 heteroatoms selected from N, O, and S and substituted with one to four groups, R1, R2, R3, and/or R4, provided that (i) A is not tetrazole or (ii) if A is thienyl or furanyl then Z is selected from a group other than succinimido or thalimido; M is selected from alkyl, cycloalkyl, aryl, heterocyclo, and heteroaryl; Ma is a linker between C and M and is selected from a bond and C1-C3alkylene; Q is selected from (i) hydrogen, halogen, nitro, cyano, hydroxy, C1-4alkyl, and substituted C1-4 alkyl; or (ii) Q is combined with R6 and with the carbon atoms to which they are attached to form a 3- to 6-membered cycloalkyl; or (iii) Q and M are combined with the carbon atom(s) to which they are attached to form a 3- to 7-membered ring containing 1-2 heteroatoms which are independently selected from the group consisting of O, S, SO2, and N which ring may be optionally substituted with 0-2 R5 groups or carbonyl; and Z is selected from alkyl, CF3, OH, cycloalkyl, heterocyclo, aryl, heteroaryl, -C(=O)NR8R9, -C(=O)R8, -C(NCN)NR8R9, -C(=O)OR8, -SO2R8, and -SO2NR8R9. Ma, Za, R1, R2, R3, R5a, R6, R7, R8, R9 and R22 are as defined herein. Also provided are pharmaceutical compositions, combinations and methods of treating metabolic and inflammatory or immune associated diseases or disorders using said compounds.